帕利哌酮缓释剂与奥氮平治疗精神分裂症疗效及对认知功能影响对照研究  

A comparative study of paliperidone sustained-release tablet and olanzapine to improve clinical symptoms and cognitive function in patients with schizophrenia

作　　者：韩攸村 黄同旭 

机构地区：[1]滨州市优抚医院,山东滨州256600

出　　处：《精神医学杂志》2017年第1期53-55,共3页Journal of Psychiatry

摘　　要：目的探讨帕利哌酮缓释片对精神分裂症患者临床疗效与认知功能改善的作用。方法选取精神分裂症的患者120例,随机分为观察组和对照组各60例。观察组患者给予帕利哌酮缓释片治疗,对照组患者给予奥氮平治疗,观察时间为3个月。于治疗前、治疗后1月末、2月末、3月末采用阳性和阴性综合征量表(PANSS)、MATRICS共识认知成套测验(MCCB)进行评估。结果观察组治疗后第1、2、3个月末PANSS总分及各因子分均较治疗前降低(P<0.05),对照组治疗后第2、3个月末PANSS总分及各因子分均较治疗前降低(P<0.05)。治疗后第1、2个月末PANSS总分及各因子分均均低于对照组(P<0.05)。观察组治疗后第1、2、3个月末MCCB除连线因子外其他各因子均较治疗前升高(P<0.05);对照组治疗后第2、3个月末MCCB符号编码因子较治疗前升高(P<0.05),治疗后第3个月末MCCB社会认知、视觉学习、推理能力因子较治疗前升高(P<0.05)。观察组治疗后第1、2、3个月末MCCB除连线因子外其他各因子均高于对照组(P<0.05)。结论帕利哌酮缓释剂治疗急性精神分裂症疗效与奥氮平相当,但临床起效时间早于奥氮平治疗,对认知功能改善作用优于奥氮平。Objective To explore efficacy of paliperidone sustained-release tablet and olanzapine to improve clinical symptoms and cognitive function in patients with schizophrenia.Methods A total of 120 patients with schizophrenia were randomly divided into study group（n = 60） with paliperidone sustained-release tablet and control group（n = 60） with olanzapine for 3 months of treatment.They were assessed with Positive and Negative Syndrome Scale（PANSS） and MATRICS Consensus Cognitive Battery（MCCB） before and at the end of the 1st,2nd and 3rd month of treatment.Results In study group,the total score and all factor scores of PANSS at the end of the 1st,2nd and 3rdmonth of treatment were all significantly lower than those before treatment（P〈0.05）.In control group,the total score and all factor scores of PANSS at the end of the 2nd and 3rdmonth of treatment were all significantly lower than those before treatment（P〈0.05）.At the end of the 1st and 2ndmonth of treatment,the total score and all factor scores of PANSS in study group were all significantly lower than those in control group（P〈0.05）.In study group,all factor scores except connection factor score of MCCB at the end of the 1st,2nd and 3rdmonth of treatment were all significantly higher than those before treatment（P〈0.05）.In control group,the coding factor score of MCCB at the end of the 2ndand 3rdmonth of treatment was significantly higher than that before treatment（P〈0.05） and the factor scores of social cognitive,visual learning,reasoning ability of MCCB at the end of the 3rdmonth of treatment were all significantly higher than those before treatment（P〈0.05）.At the end of the 1st,2nd and 3rdmonth of treatment,all factor scores except connection factor score of MCCB in study group were all significantly higher than those in control group（P〈0.05）.Conclusion It＇s effective for paliperidone sustained-release tablet and olanzapine to improve clinical symptoms and cognitive function in patients with schizophrenia,a

关 键 词：精神分裂症 帕利哌酮 奥氮平 认知功能 

分 类 号：R749.3[医药卫生—神经病学与精神病学]